Citations

Clear

585 citation(s) found for "Tran, Ha".

Mathematical Modeling of Eyebrow Curvature
Tran, Ann Q. , Yang, Cameron, Tooley, Andrea A. , Kazim, Michael, Glass, Lora R. Dagi

Mayo Clinic

Facial Plastic Surgery | February 4, 2022 | Volume: 38 | Issue: 03 | Pages: 307-310

10.1055/s-0041-1742200 | PMID 35114713 Get It

AbstractThe aim of the study is to describe a mathematical model for analyzing eyebrow curvature that can be applied broadly to curvilinear facial features. A total of 100 digital images (50 men, 50 women) were obtained from standardized headshots of medical professionals. Images were analyzed in ImageJ by plotting either 8 or 15 points along the inferior-most row of contiguous brow cilia. A best-fit curve was automatically fit to these points in Microsoft Excel. The second derivative of the second-degree polynomial and a fourth-degree polynomial were used to evaluate brow curvature. Both techniques were subsequently compared with each other. A second-degree polynomial and fourth-degree polynomial were fit to all eyebrows. Plotting 15 points yielded greater goodness-of-fit than plotting 8 points along the inferior brow and allowed for more sensitive measurement of curvature across all images. A fourth-degree polynomial function provided a closer fit to the eyebrow than a second-degree polynomial function. This method provides a simple and reliable tool for quantitative analysis of eyebrow curvature from images. Fifteen-point plots and a fourth-degree polynomial curve provide a greater goodness-of-fit. The authors believe the described technique can be applied to other curvilinear facial features and will facilitate the analysis of standardized images.
Immediate Breast Reconstruction Using the Goldilocks Procedure: A Balance between More Surgery and Patient Satisfaction
Manrique, Oscar J. , Yan, María , Bustos, Samyd S. , Harless, Christin A., Tran, Nho V. , Martinez‐Jorge, Jorys, Forte, Antonio J. , Nguyen, Minh-Doan T. , Martinez-Jorge, Jorys, Forte, Antonio Jorge , Bustos, S S , Kuruoglu, Doga , Boughey, Judy C.

Mayo Clinic

Plastic & Reconstructive Surgery | February 1, 2022 | Volume: 149 | Issue: 4 | Pages: 801-809

10.1097/prs.0000000000008895 | PMID 35103645 Get It

Background: Since its first description in 2012, the Goldilocks procedure has become an option for immediate breast reconstruction, particularly for obese patients who are poor candidates for traditional implant or autologous reconstruction. In this work, the authors performed a longitudinal study of patients who underwent mastectomy with Goldilocks reconstruction to assess the incidence of additional surgical procedures, and to assess surgical outcomes and patient satisfaction. Methods: A retrospective review of patients who underwent mastectomy with the Goldilocks procedure only at Mayo Clinic Rochester between January of 2012 and September of 2019 was performed. Demographics, complications, additional breast procedures performed to attain the final results, and patient-reported outcomes using the BREAST-Q were recorded. Univariate and multivariable analyses were performed to identify statistical associations and risk factors. Results: Sixty-three patients (108 breasts) were included. Mean age was 57.8 years. Mean body mass index was 37.6 kg/m2. Median follow-up time after the mastectomy with the Goldilocks procedure was 15 months. The major complication rate within the first 30 days was 9.3 percent. Forty-four breasts (40.7 percent) underwent additional surgery. Dyslipidemia was significantly associated with an increased risk of additional surgery (adjusted hazard ratio, 2.00; p = 0.045). Scores in the four BREAST-Q domains were not statistically different between patients who had additional procedures and those who did not. Conclusions: Based on the results, the authors recommend a thorough preoperative discussion with patients who are candidates for the Goldilocks procedure to explore all options for reconstruction and their expectations, because it is crucial to reduce the necessity for additional operations in this high-risk population. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
Abdominal Panniculectomy: An Analysis of Outcomes in 238 Consecutive Patients over 10 Years
Salinas, Cristina A., Tran, Nho V. , Nguyen, Minh-Doan T. , Martinez‐Jorge, Jorys, Bite, Uldis, Harless, Christin A., Sharaf, Basel , Martinez-Jorge, Jorys, Sharaf, Basel A , Kuruoglu, Doga

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | February 1, 2022 | Volume: 9 | Issue: 11 | Pages: e3955

10.1097/gox.0000000000003955 | PMID 34840922 Get It

Background: Panniculectomy is a commonly performed body contouring procedure to address skin laxity and its related complications. This study aimed to assess clinical outcomes of abdominal panniculectomy and identify predictors of complications at a tertiary academic healthcare center. Methods: A retrospective review of patients who underwent panniculectomy between January 2010 and January 2020 at our institution was performed. Exclusion criteria were a history of prior panniculectomy or abdominoplasty. Patient characteristics and clinical outcomes were collected. Univariate and multivariable analyses were performed to assess the risk factors of complications. Results: The mean age in the included 238 patients was 51.7 ± 12.7 years, and the mean body mass index (BMI) at the time of panniculectomy was 33 ± 7.5 kg/m 2 . Median resection weight was 2.7 kg (range: 0.15–14.6) and median length of hospital stay was 2 days (range: 0–24). Mean follow-up time was 50 ± 37 months. The rate of major complications was 22.3%. Revision surgery was performed in 3.4% of the cases. Multivariable analyses demonstrated that increase in BMI ( P = 0.007) and active smoking ( P = 0.026) were significantly associated with increased odds of major complication, and increase in BMI ( P = 0.0004), history of venous thromboembolism ( P = 0.034) and having a concomitant ventral hernia repair ( P = 0.0044) were significantly associated with having a length of hospital stay of 3 days or more. Conclusions: Panniculectomy is generally safe to perform, with major postoperative complication rate of 22.3% in our series. Increase in BMI and active smoking were significantly associated with having a major complication. Higher BMI, concomitant hernia repair, and a history of venous thromboembolism were associated with length of hospital stay of 3 days or more.
3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
Yan, Yuqian , Shao, Jingwei , Ding, Donglin , Pan, Yunqian , Tran, Phuc , Li, Hongyu , Huang, Haojie , Huang, Rui , Yan, Wei , Wang, Zhenyu

Mayo Clinic

Chemical Communications | January 26, 2022 | Volume: 58 | Issue: 14 | Pages: 2383-2386

10.1039/d1cc06525d | PMID 35080528 Get It

In this study, we discovered 3-aminophthalic acid as a new ligand of cereblon (CRBN) E3 ubiquitin ligase and developed a phthalic acid-based O’PROTAC for ERG destruction, expanding the pool of ligands for development of PROTACs, especially O’PROTACs.
P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
Loftus, Eimear, Higgins, Peter , Lindsay, JO, Zhou, Wen , Yao, Xuan , Ilo, Dapo, Phillips, Charles M., Tran, J, González, Yuri Sánchez , Panés, Julián , Loftus, E V J, Vermeire, Séverine

Mayo Clinic

Journal of Crohn's and Colitis | January 21, 2022 | Volume: 16 | Issue: Supplement_1 | Pages: i373-i374

10.1093/ecco-jcc/jjab232.497 Get It

Abstract Background Health-related quality of life (HRQOL) is reduced in patients (pts) with ulcerative colitis (UC). We report on the HRQOL benefits of maintenance treatment with upadacitinib (UPA), a selective and reversible Janus kinase inhibitor, in pts with moderately to severely active UC in the Phase, 3 multicentre, randomised, double-blind U-ACHIEVE maintenance study (NCT02819635). Methods This study included a primary analysis of, 451 pts who achieved clinical response following treatment with UPA, 45 mg once daily (QD) in two replicate, 8-week induction studies, U-ACHIEVE induction, and U-ACCOMPLISH (NCT03653026). In U-ACHIEVE maintenance, pts from both induction studies were re-randomised, 1:1:1 to receive QD UPA, 15 mg, UPA, 30 mg, or PBO. HRQOL outcomes evaluated included the percent of pts reporting a clinically meaningful within-person change (MWPC) from induction baseline to Week, 0 (maintenance baseline) and Week, 52 (end of maintenance) in a broad range of HRQOL measures, including Inflammatory Bowel Disease Questionnaire (IBDQ), Work Productivity and Impairment Questionnaire (WPAI), Short Form, 36 (SF-36), European Quality of Life-5 Dimensions, 5 Levels (EQ-5D-5L), and Ulcerative Colitis Symptoms Questionnaire (UC-SQ). Results A total of, 149, 148, and, 154 pts received PBO, UPA, 15 mg, and UPA, 30 mg QD, respectively, during maintenance. At Week, 0 of the maintenance study, there were no significant differences between UPA and PBO treatment groups in the percentage of pts reporting MWPC relative to induction baseline for most pt-reported outcomes (PROs) as all pts enrolled in maintenance were UPA clinical responders during IP. For IBDQ, a significantly greater proportion of pts achieved MWPC criteria (p<0.001) with UPA, 15 mg (68.9%) and UPA, 30 mg (78.6%) vs, 39.6% for PBO at Week, 52 (Figure, 1). Also, a significantly greater proportion of pts treated with either, 15 mg or, 30 mg UPA dosage vs PBO over, 52 weeks achieved MWPC for the WPAI domains (p≤0.01) of overall work improvement, presenteeism, and activity impairment (Figure, 2), in both physical and mental component summaries of SF-36 (p<0.001, Figure, 3), in EQ-5D-5L (p<0.001, Figure, 4), and in UC-SQ (p<0.001). A numerically greater proportion of pts receiving UPA, 30 mg vs, 15 mg achieved MWPC in most PROs at Week 52. Conclusion A significantly higher percentage of pts with moderately to severely active UC who responded to UPA induction therapy maintained clinically meaningful improvements with UPA, 15 mg of, 30 mg compared to PBO consistently across a broad range of HRQOL outcomes after, 52 weeks of maintenance treatment. These HRQOL aspects include IBD symptoms (IBDQ, UC-SQ), work productivity (WPAI), physical and mental functioning (SF-36), and general well-being (IBDQ, EQ-5D).
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
Kishan, Amar U. , Steigler, Alison, Zapatero, A. , Guerrero, A., Joseph, David , Maldonado, Xavier , Wong, J.K. , Stish, Bradley J. , Dess, Robert T. , Pilar, Avinash , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Karnes, R. Jeffrey , Tosoian, Jeffrey J. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Martin, Ting , Philipson, R., Chang, Albert J. , Kupelian, Patrick A. , Feng, Felix Y. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Spratt, Daniel E. , Romero, Tahmineh , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Ma, Ting Martin , Steigler, Allison , Denham, James William , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Song, Daniel Y. , Tilki, Derya , Jiang, Tommy , Xiang, Michael H. , Rettig, Matthew B. , Berlin, Alejandro , Tward, Jonathan D. , Boutros, Paul C.

Mayo Clinic

JAMA Oncology | January 20, 2022 | Volume: 8 | Issue: 3 | Pages: e216871

10.1001/jamaoncol.2021.6871 | PMID 35050303 Get It

Clinical outcomes of neoadjuvant treatment strategies in localized mismatch repair-deficient rectal cancer.
Soderberg, Leah C, Wookey, Vanessa, Mitchell, Jessica L. , Jochum, Jacob A., Mathis, Kellie L. , Soderberg, Leah , Tran, Nguyen H. , Hálfdánarson, Þorvarður R. , Hubbard, Joleen M. , Graham, Rondell P. , Mahipal, Amit , Jin, Zhaohui

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 192-192

10.1200/jco.2022.40.4_suppl.192 Get It

192 Background: Rectal cancer treatment paradigm has been evolving over time. Historically, for locally advanced rectal cancer, standard therapy (ST) consisted of neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Recently, total neoadjuvant treatment (TNT) approach that delivers both neoadjuvant chemotherapy (CAPOX or FOLFOX) and chemoradiation (or radiation only) prior to surgery is increasingly being utilized. The prognostic and predictive values of mismatch repair deficient (dMMR) in rectal cancer is not well characterized. Most dMMR patients receive the same treatment as MMR proficient (pMMR) patients although there is limited data that dMMR rectal cancer patients may not have the same level of benefits from neoadjuvant treatment. This retrospective study aims to evaluate the clinicopathological/molecular characteristics, disease response, and clinical outcomes in dMMR localized rectal cancer patients. Methods: A retrospective analysis was conducted on consecutive adult patients with a diagnosis of dMMR rectal cancer who were treated at Mayo Clinic between January 2000 to September 2021. Patients who presented with concurrent primary non-colorectal malignancies were excluded. The distributions of demographics, clinicopathological features, biomarkers, and outcome data were collected. Survival was assessed using Kaplan-Meier curves and Cox models were stratified by treatment arms to determine significance of treatment strategies. Results: Forty-one patients were identified with a median age of 45.3 years. Thirty (73.2%) pts were male. The most common MMR were loss of MSH2 and MSH6 (12/42; 29.3%) followed by loss of MLH1 and PMS2 (10/42; 24.4%) and solitary loss of MSH2 (4/42; 9.8%). The treatment, pathological response, and clinical outcomes are listed in table. With a median follow up of 101 months, only 6 patients (14.3%) died and median overall survival was not reached. Conclusions: Our findings showed dMMR localized rectal cancer responded to both ST and TNT with good clinical outcomes.[Table: see text]
Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty
Weissler, Jason M., Antezana, Luis A. , Curiel, Daniel , Kerivan, Lauren, Alsayed, Ahmed , Banuelos, Joseph, Harless, Christin A., Sharaf, Basel , Vijayasekaran, Aparna , Martinez‐Jorge, Jorys, Tran, Nho V. , Nguyen, Minh-Doan T. , Antezana, Luis , Sharaf, Basel A, Martinez-Jorge, Jorys, Sharaf, Basel A , Kuruoglu, Doga

Mayo Clinic

Aesthetic Surgery Journal | January 14, 2022 | Volume: 42 | Issue: 6 | Pages: 616-625

10.1093/asj/sjab399 | PMID 35029651 Get It

Abstract Background Tranexamic acid (TXA) has gained increasing recognition as a valuable pharmacologic agent within plastic surgery. Objectives The aim of this study was to investigate the value and safety profile of both intravenous and topically administered TXA in the setting of bilateral reduction mammaplasty. Methods A retrospective review was performed to identify consecutive patients who underwent bilateral reduction mammaplasty for symptomatic macromastia (January 2016-July 2021). Pertinent preoperative, intraoperative, and postoperative details were collected/reviewed. Primary outcome measures included hematoma requiring surgical evacuation and clinically significant/symptomatic seroma formation mandating percutaneous aspiration. Patients taking anticoagulation/antiplatelet medication or those with a history of thromboembolic diseases were excluded. Patients who had received TXA were compared to a historical control group who did not receive TXA within the same consecutive cohort. Results A total of 385 consecutive patients (770 breasts) were included. TXA was used in 514 (66.8%) cases (topical, 318 [61.9%]; intravenous, 170 [33.1%]; intravenous and topical, 26 [5.1%]). Neither seroma nor hematoma were impacted/reduced with TXA (P > 0.05). Increased age (hazards ratio, 1.06 per 1-year increase; 95% CI, 1.004-1.118) significantly increased the risk of hematoma (P = 0.032). The use of drains significantly decreased the risk of seroma (P < 0.0001). Increased BMI increased the risk of seroma (hazards ratio, 1.16 per 1-kg/m2 increase; 95% CI, 1.06-1.26; P = 0.0013). The use of TXA did not impact drain duration. Conclusions This study, the largest to date on the use of IV and topical TXA, did not find any reduction in risk when using TXA in breast reduction surgery. Level of Evidence: 3
Isocitrate Dehydrogenase–Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes
Wintheiser, Grant , Zemla, Tyler, Shi, Qian, Tran, Nguyen H. , Prasai, Kritika, Tella, Sri Harsha, Mody, Kabir , Ahn, Daniel, Borad, Mitesh J. , Bekaii‐Saab, Tanios , Shi, Qian , Tran, Nguyen , Borad, Mitesh J , Mahipal, Amit , Shi, Qian , Wintheiser, Grant A , Bekaii-Saab, Tanios S , Zemla, Tyler, Shi, Qian, Prasai, Kritika, Tella, Sri Harsha, Mody, Kabir , Ahn, Daniel

Mayo Clinic

JCO Precision Oncology | January 5, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00156 | PMID 35005992 Get It

Purpose Clinical-pathologic features and natural history of patients with isocitrate dehydrogenase ( IDH)-mutant intrahepatic cholangiocarcinoma (CCA) are not well characterized. Here, we sought to describe the natural history, clinical phenotype, and prognostic impact of advanced, IDH-mutated CCA. METHODS We conducted a multicentric, retrospective analysis of patients with IDH-mutated (IDH1 or IDH2) CCA between 2010 and 2020. Median overall survival (OS) and progression-free survival (PFS) analyses were performed using the Kaplan-Meier method. Chi-square test was used to analyze disease control rate (DCR) and overall response rate (ORR). Matched controls were used for comparing survival between patients with and without IDH mutations (mIDH). RESULTS Sixty-five patients with IDH-mutated CCA were included. All patients had intrahepatic CCA. On first-line chemotherapy, median OS and median PFS were 21.2 months and 8.3 months, respectively. Notably, median OS (32.4 v 19.5 months, P = .12) and PFS (18.0 v 8.0 months, P = .12) were not significantly affected by disease status at presentation (locally advanced v metastatic, respectively). Median OS was significantly longer in patients with mIDH (21.2 v 10.5 months; P < .01). First-line gemcitabine-containing regimens had a significantly higher DCR and ORR than non–gemcitabine-containing regimens (DCR: 75% v 33%, P = .01; ORR: 39% v 0%, P = .02). In patients receiving IDH inhibitor therapy, median PFS was 4.6 months with a DCR of 29%. CONCLUSION CCA with m IDH confers a unique subtype resulting in a better survival compared with that of counterparts. IDH inhibitors represent a promising therapeutic option in later lines of therapy in this subgroup.
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
Kocarnik, Jonathan , Compton, Kelly, Dean, Frances , Fu, Weijia , Gaw, Brian, Harvey, James , Henrikson, Hannah , Lu, Dan , Pennini, Alyssa, Xu, Rixing, Ababneh, Emad , Abbasi‐Kangevari, Mohsen , Abbastabar, Hedayat , Abd‐Elsalam, Sherief , Abedi, Aidin , Abidi, Hassan , Abolhassani, Hassan , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Aghaali, Mohammad , Ahmad, Tauseef , Rashid, Tarik A. , Salih, Yusra Ahmed , Aklilu, Addis , Akram, Tayyaba , Akunna, Chisom Joyqueenet , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Alkhayyat, Motasem , Almasri, Nihad A. , Al‐Maweri, Sadeq Ali , Almustanyir, Sami , Alonso, Nivaldo , Alvis‐Guzmán, Nelson , Amu, Hubert , Ansari, Fereshteh, Antwi, Maxwell Hubert , Anvari, Davood , Anyasodor, Anayochukwu Edward , Aqeel, Muhammad , Arabloo, Jalal , Aremu, Olatunde , Ariffin, Hany , Aripov, Timur , Arshad, Muhammad , Artaman, Al, Arulappan, Judie , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Atorkey, Prince , Ausloos, Marcel , Awedew, Atalel Fentahun , Quintanilla, Beatriz Paulina Ayala , Ayenew, Temesgen , Azab, Mohammed A. , Azadnajafabad, Sina , Jafari, Amirhossein Azari , Azarian, Ghasem , Badiye, Ashish , Bahadory, Saeed , Baig, Atif Amin , Baker, Jennifer L. , Balakrishnan, Senthilkumar , Bärnighausen, Till , Barone‐Adesi, Francesco , Barrow, Amadou , Belgaumi, Uzma , Bezabhe, Woldesellassie, Bezabih, Yihienew Mequanint , Bhagat, Devidas S. , Bhagavathula, Akshaya Srikanth , Bhardwaj, Nikha , Bhaskar, Sonu , Bhojaraja, Vijayalakshmi S, Bibi, Sadia , Bijani, Ali , Bisignano, Catherine, Bolarinwa, Obasanjo Afolabi , Bolla, Srinivasa Rao , Braithwaite, Dejana , Brar, Amanpreet , Brenner, Hermann , Bustamante-Teixeira, Maria Teresa , Butt, Nadeem Shafique , Butt, Zahid A , Santos, Florentino Luciano Caetano dos , Cao, Yin , Carreras, Giulia , Catalá-López, Ferrán , Cembranel, Francieli , Cerin, Ester , Cernigliaro, Achille , Chakinala, Raja Chandra , Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chimed‐Ochir, Odgerel , Cho, Daniel , Chu, Dinh‐Toi , Conde, João , Cortés, Sandra , Cortesi, Paolo Angelo, Costa, Vera Marisa , Cunha, Amanda Ramos da , Dadras, Omid , Dagnew, Amare Belachew , Dandona, Lalit , Dandona, Rakhi , Hoz, Fernando de la , Dhamnetiya, Deepak , Dhimal, Mandira Lamichhane , Díaz, Daniel , Djalalinia, Shirin , Doaei, Saeid , Dorostkar, Fariba, Driscoll, Tim , Ebrahimi, Hedyeh , Eftekharzadeh, Sahar , Tantawi, Maha El , El‐Abid, Hassan , Elbarazi, Iffat , Elhabashy, Hala Rashad , Elhadi, Muhammed , Eshrati, Babak, Esmaeilzadeh, Firooz , Etemadi, Arash , Ezzikouri, Sayeh , Faisaluddin, Mohammed, Fares, Jawad , Farzadfar, Farshad , Feroze, Abdullah , Desideri, Lorenzo Ferro , Fischer, Florian , Fisher, James L. , Fukumoto, Takeshi , Gad, Mohamed M. , Fonseca, Mariana Gaspar, Obsa, Abera Getachew, Ghafourifard, Mansour , Ghashghaee, Ahmad , Ghith, Nermin , Gholamalizadeh, Maryam , Gilani, Syed Amir , Gizaw, Abraham Tamirat , Glasbey, James , Golechha, Mahaveer , Goleij, Pouya , Gopalani, Sameer Vali , Gorini, Giuseppe , Goudarzi, Houman , Gubari, Mohammed Ibrahim Mohialdeen , Guerra, Maximiliano Ribeiro, Guha, Avirup , Gunasekera, Sanjeeva , Gupta, Bhawna , Gupta, Vivek , Gutiérrez, Reyna Alma, Hafezi‐Nejad, Nima , Haider, Mohammad Rifat , Hameed, Sajid , Hanif, Asif , Haque, Shafiul , Harlianto, Netanja I. , Hasaballah, Ahmed I , Hay, Simon I , Heidari, Golnaz , Herrera-Serna, Brenda Yuliana , Herţeliu, Claudiu , Hezam, Kamal , Hossain, Mohammad Bellal , Hosseini, Mohammad‐Salar , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela , Househ, Mowafa , Hsaïri, Mohamed, Huang, Junjie , Hugo, Fernando Neves , Hussain, Rabia , Hussein, Nawfal R , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ida, Fidelia , Ikuta, Kevin S , Ilić, Irena , Irham, Lalu Muhammad , Islam, Jessica Y. , Islam, Sheikh Mohammed Shariful , Ismail, Nahlah Elkudssiah , Isola, Gaetano , Iwagami, Masao , Jacob, Louis , Jain, Vardhmaan , Jakovljević, Mihajlo, Javaheri, Tahereh , Jayaram, Shubha, Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kalankesh, Leila R , Kalhor, Rohollah , Kalkonde, Yogeshwar , Kamath, Ashwin , Al-Salihi, Nawzad Kameran, Kandel, Himal , Kapoor, Neeti , Kasa, Ayele Semachew , Keshavarz, Pedram , Keykhaei, Mohammad , Khader, Yousef , Khalilov, Rovshan , Khan, Maseer , Khan, Md Nuruzzaman , Khan, Moien AB , Khang, Young-Ho, Khater, Amir M, Kısa, Adnan , Kısa, Sezer , Kopec, Jacek A , Koteeswaran, Rajasekaran , Koul, Parvaiz A , Laxminarayana, Sindhura Lakshmi Koulmane , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, G Anil , Kurmi, Om , Kutluk, Tezer, Lami, Faris Hasan, Lee, Yo Han , Leigh, James , Leong, Elvynna , Li, Ming‐Chieh , Liu, Xuefeng , Loureiro, Joana A. , Lunevičius, Raimundas , Razek, Muhammed Magdy Abd El, Majeed, Azeem , Makki, Alaa, Male, Shilpa, Malik, Ahmad Azam , Martini, Santi , Masoumi, Seyedeh Zahra , Mehrotra, Ravi , Mendoza, Walter, Mengesha, Endalkachew Worku , Mesregah, Mohamed Kamal , Jonasson, Junmei Miao , Miazgowski, Bartosz , Miazgowski, Tomasz , Michałek, Irmina Maria , Miller, Ted R. , Mirzaei, Hamid Reza , Misra, Sanjeev , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Mokhtar , Mohammadi, Seyyede Momeneh, Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Moka, Nagabhishek , Mokdad, Ali H. , Molokhia, Mariam , Monasta, Lorenzo , Moosavi, Mohammad Amin , Moradi, Yousef , Moraga, Paula , Morgado-da-Costa, Joana, Mubarik, Sumaira , Mwanri, Lillian , Nagarajan, Ahamarshan Jayaraman , Nagata, Chie , Naimzada, Mukhammad David , Nangia, Vinay, Naqvi, Atta Abbas , Swamy, Sreenivas Narasimha, Negoi, Ionuţ , Negru, Șerban , Kandel, Sandhya Neupane , Nguyen, Cuong Tat , Niazi, Robina Khan, Nnaji, Chukwudi A , Noor, Nurulamin M , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olakunde, Babayemi O. , Omar, Emad, Bali, Ahmed Omar , Omonisi, Abidemi , Ong, Sokking, Onwujekwe, Obinna , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Pakshir, Keyvan , Pană, Adrian , Panagiotakos, Demosthenes B. , Panda‐Jonas, Songhomitra, Park, Eun‐Cheol , Park, Eun‐Kee , Kan, Fatemeh Pashazadeh , Patel, Harsh K. , Patel, Jenil , Pati, Siddhartha , Paudel, Uttam , Pereira, David M. , Pereira, Renato B. , Perianayagam, Arokiasamy , Pillay, Julian David , Pirouzpanah, Saeed , Podder, Indrashis , Postma, Maarten J. , Prashant, Akila , Preoțescu, Liliana , Rabiee, Navid , Radfar, Amir , Radhakrishnan, Raghu , Radhakrishnan, Venkatraman , Rahim, Fakher , Rahimzadeh, Shadi , Rahman, Mosiur , Rahman, Muhammad Aziz , Rajai, Nazanin , Rajesh, Aashish , Ram, Pradhum , Ramezanzadeh, Kiana, Ranabhat, Kamal , Rao, Chythra R , Rao, Sowmya J, Rawassizadeh, Reza , Razeghinia, Mohammad Sadegh , Rezapour, Aziz, Buendía, Jefferson Antonio , Rohloff, Peter , Rwegerera, Godfrey Mutashambara , Manjula, S, Saddik, Basema , Saeed, Umar , Sahoo, Harihar , Salehi, Sana , Salem, Marwa Rashad , Samaei, Mehrnoosh, Samy, Abdallah M , Sanabria, Juan , Sankararaman, Senthilkumar , Santric-Milicevic, Milena M , Sardiwalla, Yaeesh , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Šekerija, Mario , Seylani, Allen, Shafaat, Omid , Shaikh, Masood Ali , Shannawaz, Mohammed , Sheikhbahaei, Sara , Shetty, Adithi , Shetty, Jeevan K. , Shetty, Pavanchand H, Shirkoohi, Reza , Shivarov, Velizar , Malleshappa, Sudeep K Siddappa , Silva, Diego Augusto Santos , Sintayehu, Yitagesu , Skryabin, Valentin Yurievich , Soeberg, Matthew, Sofi‐Mahmudi, Ahmad , Steiropoulos, Paschalis , Straif, Kurt, Subedi, Ranjeeta , Sultana, Saima , Szerencsés, Viktória , Tabuchi, Takahiro , Tadbiri, Hooman , Takahashi, Ken , Tan, Ker‐Kan , Tat, Vivian Y, Tedla, Bemnet , Tefera, Yonas Getaye , Temsah, Mohamad‐Hani , Tesfay, Fisaha Haile , Tessema, Gizachew Assefa , Thavamani, Aravind , Chandrasekar, Viveksandeep Thoguluva , Touvier, Mathilde , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Mai Thi Ngoc , Tripathy, Jaya Prasad , Tusa, Biruk Shalmeno , Ullah, Irfan , Ullah, Saif , Umapathi, Krishna Kishore , Vaezi, Maryam, Tahbaz, Sahel Valadan , Velazquez, Diana Zuleika , Violante, Francesco Saverio , Volovici, Victor , Vu, Giang Thu , Waheed, Yasir , Ward, Paul , Wen, Yi Feng , Westerman, Ronny, Yadav, Lalit , Jabbari, Seyed Hossein Yahyazadeh, Yang, Lin , Yazie, Taklo Simeneh , Yeshaw, Yigizie , Younis, Mustafa Z , Yousefi, Zabihollah , Yunusa, Ismaeel , Zadnik, Vesna , Zare, Fariba , Застрожин, Михаил Сергеевич , Zastrozhina, Anasthasia, Zhang, Jianrong , Zhong, Chenwen, Zhu, Cong , Zimmermann, Ivan Ricardo , Fitzmaurice, Christina , Murray, Christopher J L , Force, Lisa M , Ong, Sok King , Eftekhari, Aziz , Guimarães, André Luiz Sena , Kumar, Vivek , Lami, Faris , Liu, Xuefeng , Baig, Atif Amin , Thoguluva Chandrasekar, Viveksandeep, Kumar, Vivek , Cao, Yin , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Guha, Avirup , Ebrahimi, Hedyeh , Volovici, Victor , Bhagavathula, Akshaya Srikanth , Jakovljević, Mihajlo , Elhadi, Muhammed , Abdoli, Amir , Adnani, Qorinah Estiningtyas Sakilah , Afzal, Muhammad Sohail, Ahinkorah, Bright Opoku , Ahmad, Sajjad , Ahmadi, Ali , Ahmadi, Sepideh , Akalu, Gizachew Taddesse , Al‐Aly, Ziyad , Ali, Saqib , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Anbesu, Etsay Woldu , Ancuceanu, Robert , Ansari‐Moghaddam, Alireza , Arab-Zozani, Morteza , Asemi, Zatollah , Aujayeb, Avinash , Azzam, Ahmed Y , Banach, Maciej , Barra, Fabio , Behzadifar, Masoud , Bezabhe, Woldesellassie M Mequanint , Bhardwaj, Pankaj , Bhattacharyya, Krittika , Biondi, Antonio , Bjørge, Tone , Bleyer, Archie , Blyuss, Oleg B. , Chaturvedi, Pankaj, Christopher, Devasahayam Jesudas , Chung, Michael T. , Cortesi, Paolo Angelo , Belachew, Amare , Dahlawi, Saad M A , Dai, Xiaochen , Darwesh, Aso Mohammad , Neves, José das , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Dhimal, Meghnath , Dianatinasab, Mostafa , Do, Huyen Phuc , Doaei, Saeid , Figueiredo, Francisco Winter dos Santos , El-Jaafary, Shaimaa I , Eskandarieh, Sharareh , Faraon, Emerito Jose A , Ferrero, Simone , Filip, Irina , Foroutan, Masoud , Gaál, Péter , Gadanya, Muktar A , Gallus, Silvano , Gomez, Ricardo Santiago , Grosso, Giuseppe , Gupta, Veer Bala , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hamadeh, Randah R , Hamidi, Samer , Haro, Josep María , Hassanipour, Soheil , Hay, Roderick J. , Hayat, Khezar , Heidari, Mohammad , Holla, Ramesh , Hossain, Md Mahbub , Hostiuc, Sorin , Iavicoli, Ivo , Ilesanmi, Olayinka Stephen , Ilić, Milena , Islam, Rakibul M. , Jazayeri, Seyed Behzad , Kabir, Ali , Kahrizi, Danial , Kaliyadan, Feroze , Karch, André , Katikireddi, Srinivasa Vittal , Kauppila, Joonas H. , Kavetskyy, Taras , Kebede, Sewnet Adem , Khan, Gulfaraz , Khang, Young-Ho, Khayamzadeh, Maryam , Kim, Gyu Ri , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Kumar, Narinder , Kumar, Nithin , Vecchia, Carlo La , Landires, Iván , Lauriola, Paolo , Lee, Sang Hyuck , Lee, Shaun Wen Huey , Lee, Wei‐Chen , Li, Jiarui , Mansournia, Mohammad Alì , Mathur, Prashant , McKee, Martin , Menezes, Ritesh G. , Meštrović, Tomislav , Mirzaei, Hamed , Moni, Mohammad Ali , Morrison, Shane D. , Mosapour, Abbas , Nagaraju, Shankar Prasad , Ndejjo, Rawlance , Nduaguba, Sabina O. , Nguyen, Huong Lan Thi , Núñez-Samudio, Virginia , Оchir, Chimedsuren , Odukoya, Oluwakemi Ololade , Ong, Sokking, Orru, Hans , Otstavnov, Nikita , Owolabi, Mayowa , Padubidri, Jagadish Rao , Pardhan, Shahina , Pattanshetty, Sanjay M. , Pishgar, Farhad , Pourjafar, Hadi , Rabiee, Mohammad , Rafiee, Ata , Rahmani, Amir Masoud , Rakovac, Ivo , Ranasinghe, Priyanga Diloshini , Renzaho, André M. N. , Rezaei, Negar , Rezaei, Nima , Roberts, Thomas J. , Romoli, Michele , Ronfani, Luca , Roshandel, Gholamreza , Sabour, Siamak , Sahebkar, Amirhossein , Salimzadeh, Hamideh , Şaylan, Mete , Schneider, Ione Jayce Ceola , Shaghaghi, Zahra , Shamsoddin, Erfan , Sharma, Rajesh , Sheikh, Aziz , Shibuya, Kenji , Shivakumar, K. M. , Siabani, Soraya , Singh, Jasvinder A. , Skryabina, Anna Aleksandrovna , Sotoudeh, Houman , Sufiyan, Mu’awiyyah Babale , Sultan, Iyad Yasin , Sur, Daniel Genel , Szócska, Miklós , Tabarés‐Seisdedos, Rafael , Taherkhani, Amir , Talaat, Iman Mamdouh , Tehrani‐Banihashemi, Arash , Thapar, Rekha , Thomas, Nihal , Tohidinik, Hamid Reza , Tran, Bach Xuan , Tran, Khanh Bao , Unnikrishnan, Bhaskaran , Upadhyay, Era , Vacante, Marco , Vaezi, Maryam, Veroux, Massimiliano , Vlassov, Vasily , Vo, Bay, Wamai, Richard G. , Winkler, Andrea Sylvia , Yaya, Sanni , Yonemoto, Naohiro , Yu, Chuanhua , Yüce, Deniz , Zhou, Linghui , Ziapour, Arash , Olagunju, Andrew T , Shivakumar, KM , Baig, Atif Amin , Alahdab, Fares , Asghari-Jafarabadi, Mohammad , Rahim, Fakher

Mayo Clinic

JAMA Oncology | December 30, 2021 | Volume: 8 | Issue: 3 | Pages: 420

10.1001/jamaoncol.2021.6987 | PMID 34967848 Get It